AstraZeneca doubles down on $80B target amid catalyst-rich 2026 pipeline. With more than 100 phase 3 trials underway with 20+ readouts expected this year, the company faces both blockbuster opportunity and Farxiga's patent cliff risk.

Alnylam posted its first-ever GAAP profit in 2025, reporting $314 million in net income. Amvuttra’s rapid ATTR-CM expansion drove the turnaround, though Q4 sales modestly missed expectations. Meanwhile, competitive pressure from Pfizer and BridgeBio is reshaping the ATTR-CM landscape. and pricing dynamics and early-year volatility may weigh on near-term performance despite strong full-year guidance.

Infigratinib met the primary endpoint in the phase 3 Propel 3 trial in achondroplasia. It drug demonstrated statistically significant improvements in annualized height velocity and body proportionality. Analysts characterized the data as a “best-case scenario,” strengthening the case for premium pricing. Regulatory submission is expected in the second half of the year amid increasing competition in the dwarfism market.

Moderna received a refusal-to-file (RTF) letter for its next-generation mRNA flu vaccine, the FDA citing concerns over the trial’s control arm design. Analysts warn the decision may complicate Moderna’s flu-COVID combination strategy, with policy shifts suggesting increased scrutiny of mRNA platforms in the U.S.

We've had Eyes on the evolving Pharma Pipeline Strategy. This week we highlight how many companies are leaning on external innovation with full acquisition s to targeted asset deals to drive long-term strategy.

In Part 4 of our Series on how the pharma landscape is being reshaped - from the inside out, we have Eyes On what late-stage setbacks and tolerability trade-offs reveal about portfolio planning and platform expansion.